Analyst consensus rating
Palvella Therapeutics Analyst Rating: Strong Buy
PVLA is rated Strong Buy by 15 analysts with a $230.53 target. As of 2026-09-01.
Direct answer
Palvella Therapeutics's consensus rating is Strong Buy.
15 analysts are included in the current consensus when a coverage count is available.
The same consensus reports an average price target of $230.53.
Forecast evidence checked September 1, 2026.
Get free Palvella Therapeutics email updates.
Bullstory sends one daily email when new analysis or important company news is available.
Verified data
- Current price
- $152.59
- Average price target
- $230.53
- High price target
- $270.00
- Low price target
- $205.00
- Low target gap
- +34.3%
- Target upside
- +51.1%
- High target gap
- +76.9%
- Target range width
- 42.6%
- Consensus rating
- Strong Buy
- Analysts
- 15
- Evidence date
- September 1, 2026
- Valid through
- September 8, 2026
Explore related company data
Read the frequently asked questions.
What is the analyst consensus rating for Palvella Therapeutics?
Palvella Therapeutics has a verified Strong Buy consensus. The same dataset has an average price target of $230.53.
How far are Palvella Therapeutics's low and high targets from the recorded price?
The low target implies +34.3%, while the high target implies +76.9%.
How many analysts are included in Palvella Therapeutics's consensus?
The verified consensus includes 15 analysts.
How is Palvella Therapeutics's target upside or downside calculated?
The average target of $230.53 is divided by the recorded price of $152.59, then one is subtracted to produce +51.1%. This does not guarantee a future return.
When was Palvella Therapeutics's analyst forecast verified?
The data was verified on 2026-09-01. The dataset is valid through 2026-09-08.